Trends in prevalence in human papillomavirus types and their association with cervical dysplasia: an analysis on 15 138 women over 20 years.
Adult
Female
Follow-Up Studies
Humans
Italy
/ epidemiology
Papillomaviridae
/ classification
Papillomavirus Infections
/ complications
Papillomavirus Vaccines
/ administration & dosage
Prevalence
Prognosis
Retrospective Studies
Uterine Cervical Neoplasms
/ epidemiology
Uterine Cervical Dysplasia
/ epidemiology
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
3
8
2020
pubmed:
3
8
2020
medline:
31
8
2021
Statut:
ppublish
Résumé
To investigate trends in prevalence of various human papillomavirus types in order to assess the unmet clinical needs for women affected by human papillomavirus-related disease. Data of consecutive 15 138 patients undergoing human papillomavirus DNA testing from 1998 to 2018 were retrospectively identified. Human papillomavirus types were classified at high-risk according to the classification of the International Agency for Research on Cancer. The International Agency for Research on Cancer included seven human papillomavirus types covered by nine-valent vaccine and five not yet covered by any available vaccines. Overall, 4159 (65.3%), 1500 (23.5%) and 714 (11.2%) women had human papillomavirus types covered by nine-valent vaccination, not covered by nine-valent vaccination and co-infections of human papillomavirus types of both groups. At least one high-risk human papillomavirus type(s) was detected in 1241 patients with genital dysplasia: 832 (67.1%), 291 (23.4%) and 118 (9.5%) women had human papillomavirus types covered by nine-valent vaccination, not covered by nine-valent vaccination and co-infections of human papillomavirus types of both groups. Over the twenty-year study period, the number of human papillomavirus types not covered by nine-valent vaccine increased dramatically (from 4 to 16%; P < 0.001, P for trend). Similarly, looking at patients with genital dysplasia, high-risk human papillomavirus types not covered by nine-valent vaccine increased from 3 to 13% (P < 0.001, P for trend). Our data highlight that human papillomavirus types covered by nine-valent vaccine represent are the main types associated with genital dysplasia. However, over the study period, we observed an increasing prevalence of confections and high-risk human papillomavirus types not covered by the nine-valent vaccine, thus suggesting the need of developing more complete vaccines against human papillomavirus.
Identifiants
pubmed: 32740171
doi: 10.1097/CEJ.0000000000000565
pii: 00008469-202009000-00010
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
452-457Références
Aro K, Nieminen P, Louvanto K, Jakobsson M, Virtanen S, Lehtinen M, et al. Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. Gynecol Oncol. 2019; 154:354–359
Bogani G, Tagliabue E, Ferla S, Martinelli F, Ditto A, Chiappa V, et al. Nomogram-based prediction of cervical dysplasia persistence/recurrence. Eur J Cancer Prev. 2019; 28:435–440
Bogani G, Taverna F, Lombardo C, Borghi C, Martinelli F, Signorelli M, et al. Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology. Int J Gynaecol Obstet. 2017; 138:62–68
Bogani G, Taverna F, Lombardo C, Signorelli M, Chiappa V, Casarin J, et al. Potential impact of introducing a nonavalent HPV vaccination. Int J Gynaecol Obstet. 2018; 142:338–342
Centers of Disease Control and Prevention (CDC). Human Papillomavirus. 2019. https://www.cdc.gov/hpv/parents/about-hpv.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fhpv%2Fparents%2Fwhatishpv.html. [Accessed 08/18/2019]
Dillner J, Nygård M, Munk C, Hortlund M, Hansen BT, Lagheden C, et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018; 36:3820–3829
Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol. 2018; 151:229–234
Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019; 154:110–117
IARC Working Group. Monographs. Human papillomaviruses. 2018. Available at: https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B-11.pdf. [Accessed 08/18/2019]
Innes CR, Sykes PH, Harker D, Williman JA, Van der Griend RA, Whitehead M, et al. Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016). Papillomavirus Res. 2018; 6:77–82
Joura EA, Kyrgiou M, Bosch FX, Kesic V, Niemenen P, Redman CW, Gultekin M. Human papillomavirus vaccination: the ESGO-EFC position paper of the european society of gynaecologic oncology and the european federation for colposcopy. Eur J Cancer. 2019; 116:21–26
Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017; 17:1293–1302
Markowitz LE, Naleway AL, Lewis RM, Crane B, Querec TD, Weinmann S, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the united states: evidence of direct and herd effects of vaccination. Vaccine. 2019; 37:3918–3924
Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, Soldan K. The impact of the national HPV vaccination program in england using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016. J Infect Dis. 2018; 218:911–921
World Health Organization (WHO). Screening for cervical cancer. 2019. Available at: https://www.who.int/cancer/detection/cervical_cancer_screening/en/. [Accessed 08/18/2019]